Oncovin

(Vincristine)

ApprovedSmall molecule

Vincristine is a chemotherapy drug used to treat various cancers, including leukemia, lymphoma, and some solid tumors, by stopping cancer cells from dividing and growing.[2] Oncovin is currently approved and in use across 74 indications[4].[1]

Oncovin is one of 790 small molecule programs targeting T-cell acute lymphoblastic leukemia. It is currently in Approved.

Indications

441

Total Trials

Active Trials

789

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

T-Cell Acute Lymphoblastic LeukemiaActive, not recruiting

RetinoblastomaRecruiting

LymphomaTerminated

Diffuse Large B-Cell LymphomaTerminated

MedulloblastomaActive, not recruiting

Acute Lymphoblastic LeukemiaCompleted

TreatmentRecruiting

EfficacyCompleted

LenalidomideUnknown status

Immune ThrombocytopeniaActive, not recruiting

T-Cell Acute Lymphoblastic LeukemiaPhase 3

Active, not recruiting

RetinoblastomaPhase 2

Recruiting

LymphomaApproved

Terminated

Diffuse Large B-Cell LymphomaPhase 3

Terminated

MedulloblastomaPhase 3

Active, not recruiting

Acute Lymphoblastic LeukemiaApproved

Completed

TreatmentPhase 3

Recruiting

EfficacyPhase 3

Completed

LenalidomidePhase 2

Unknown status

Immune ThrombocytopeniaApproved

Active, not recruiting

Showing 10 of 74 indications

Competition

Competitive Landscape

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

Oncovin

Eli Lilly

Approved

99 2

Zofran

Novartis

Preclinical

2 3

Norvir

AbbVie

Preclinical

1 4

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 5

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 6

Nuvigil

NNuvo Research GmbH

Preclinical

1 7

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—9

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Systemic Therapy

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Active, not recruiting

Infants

NCT05359237

Q4 2026

Phase 1/2Recruiting

Acute Lymphoblastic Leukemia

NCT06207123

Phase 2Recruiting

Lymphoma

NCT04922567

Q1 2027

Phase 1/2Active, not recruiting

Acute Lymphoblastic Leukemia

NCT05192889

Phase 2Recruiting

Acute Lymphoblastic Leukemia

NCT04747912

Q2 2027

Phase 2Active, not recruiting

Ewing Sarcoma

NCT01864109

Clinical

Trials by Indication[1]

Lymphoma52 trials

Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)

Terminated· Pfizer logo

Pfizer·Phase 3·NCT00562965·29 enrolled

Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy

Completed·UUniversity College, London·Phase 2·NCT01679119·129 enrolled

MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine

Completed· Takeda logo

Takeda·Phase 1/2·NCT01397825·45 enrolled

Show 49 more trials

Treatment for Classical Hodgkin Lymphoma in Children and Adolescents

Recruiting·GGALIA AVRAHAMI·N/A·NCT02797717·2,200 enrolled

Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children With Relapsed and Refractory Lymphoma and Solid Tumors

Active, not recruiting·SSun Yat-sen University·Phase 1·NCT05620862·68 enrolled

Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00290433·55 enrolled

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Suspended·—·Phase 2·NCT06692452·24 enrolled

R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma

Completed·HHenan Cancer Hospital·Phase 2·NCT04214626·60 enrolled

A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT05200312·36 enrolled

GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma

Terminated·TThe Lymphoma Academic Research Organisation·Phase 3·NCT01659099·671 enrolled

Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma

Unknown status·RRuijin Hospital·Phase 2·NCT03853044·23 enrolled

Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas

Withdrawn·NNational Cancer Institute (NCI)·Phase 1/2·NCT02228512

Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00299182·50 enrolled

Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma

Completed·WWeill Medical College of Cornell University·Phase 1/2·NCT01004991·14 enrolled

Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00274924·100 enrolled

A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL

Completed· Roche logo

Roche·Phase 1/2·NCT02055820·267 enrolled

Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma

Terminated·—·Phase 2·NCT00126191·10 enrolled

PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00054665·50 enrolled

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

Recruiting·AAIDS Malignancy Consortium·Phase 1·NCT04139304·15 enrolled

Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment

Unknown status·BBritish Columbia Cancer Agency·Phase 2·NCT00324467·150 enrolled

CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study

Unknown status·RRoyal Marsden NHS Foundation Trust·Phase 2·NCT01719835·87 enrolled

SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00787527·14 enrolled

BV-AVD-R Treatment Children Hodgkin's Lymphoma

Unknown status·—·Phase 2·NCT06201507·44 enrolled

S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma

Completed·SSWOG Cancer Research Network·Phase 3·NCT00006721·571 enrolled

Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

Unknown status·SSouthwest Hospital, China·Phase 3·NCT03553537·100 enrolled

Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma

Completed·SStanford University·Phase 2·NCT00026208·76 enrolled

Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell Lymphoma

Withdrawn· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT02595242

A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma

Completed· Eisai logo

Eisai·Phase 2·NCT00211185·49 enrolled

Prospective Study on HIV-related Hodgkin Lymphoma

Unknown status·HHarlachinger Krebshilfe e.V.·Phase 2·NCT01468740·130 enrolled

Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00193479·51 enrolled

Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients

Completed·CChipscreen Biosciences, Ltd.·Phase 1·NCT02809573·30 enrolled

MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma

Withdrawn·NNational Cancer Institute (NCI)·Phase 1/2·NCT01415765

A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT02529852·59 enrolled

A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma

Completed· Roche logo

Roche·Phase 1·NCT00825149·137 enrolled

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT03755804·232 enrolled

Stage I/II Nasal NK Cell Lymphoma

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT01321008·1 enrolled

Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma

Recruiting· Gilead logo

Gilead·Phase 3·NCT05605899·300 enrolled

A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

Completed· Roche logo

Roche·Phase 1/2·NCT03677141·117 enrolled

Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda

Terminated·FFred Hutchinson Cancer Center·Phase 1·NCT03864419·18 enrolled

A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma

Completed·LLymphoma Study Association·Phase 2·NCT00169156·27 enrolled

Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma

Terminated·EECOG-ACRIN Cancer Research Group·Phase 2·NCT01390584·6 enrolled

FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma

Withdrawn·FFate Therapeutics·Phase 1·NCT05934097

Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)

Terminated·RRush University Medical Center·Phase 2·NCT02531308·5 enrolled

MabionCD20 Compared to MabThera in Lymphoma Patients

Completed·MMabion SA·Phase 3·NCT02617485·143 enrolled

Temozolomide, Nedaplatin, Vincristine, and Radiotherapy as First-line Treatment in Newly Diagnosed Primary CNS Lymphoma

Unknown status·RRongjie Tao·Phase 2·NCT01735747·16 enrolled

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT04933617·8 enrolled

Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients

Completed·MM.D. Anderson Cancer Center·N/A·NCT00651755·23 enrolled

Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT04922567·289 enrolled

Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients

Unknown status·NNanfang Hospital, Southern Medical University·Phase 3·NCT03023358·174 enrolled

Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients

Unknown status·PPeking University·Phase 2·NCT03617432·114 enrolled

Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00118209·524 enrolled

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01445535·15 enrolled

Acute Lymphoblastic Leukemia33 trials

Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00890656·90 enrolled

A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

Recruiting·UUniversity of Chicago·Phase 1/2·NCT06207123·15 enrolled

Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study

Unknown status·NNational University Hospital, Singapore·Phase 4·NCT02894645·500 enrolled

Show 30 more trials

Treatment of Acute Lymphoblastic Leukemia Ph '(BCR / ABL) Positive Patients Aged > 55 Years

Unknown status·PPETHEMA Foundation·N/A·NCT01376427·100 enrolled

Treatment of Older Adults With Acute Lymphoblastic Leukemia

Completed·MMassachusetts General Hospital·Phase 2·NCT00973752·30 enrolled

Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment

Completed·GGoethe University·Phase 3·NCT02881086·1,023 enrolled

Ma-Spore ALL 2020 Study

Recruiting·NNational University Hospital, Singapore·Phase 2·NCT06336395·500 enrolled

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Active, not recruiting· Takeda logo

Takeda·Phase 3·NCT03589326·245 enrolled

German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·GGoethe University·Phase 4·NCT00198978·377 enrolled

Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia

Completed·AAssociazione Italiana Ematologia Oncologia Pediatrica·Phase 3·NCT00613457·2,039 enrolled

Monoclonal Antibody (mAb) 216 With Chemotherapy in Adult Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia

Completed·SSteven E. Coutre·Phase 1·NCT00313079·9 enrolled

PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Active, not recruiting·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1/2·NCT03817320·24 enrolled

PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia

Completed·PPETHEMA Foundation·Phase 4·NCT00494897·374 enrolled

Study of mAb 216 With Chemotherapy for Treatment of Pediatric Relapsed or Refractory B-progenitor Acute Lymphoblastic Leukemia

Terminated·CClare Twist·Phase 1·NCT00313053·4 enrolled

Pulses of Vincristine and Dexamethasone in BFM Protocols for Children With Acute Lymphoblastic Leukemia

Completed·IInternational BFM Study Group·Phase 4·NCT00411541·2,600 enrolled

Treatment of Acute Lymphoblastic Leukemia in Children

Completed·—·Phase 3·NCT00165178·498 enrolled

Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia

Unknown status·PPETHEMA Foundation·Phase 2·NCT02776605·30 enrolled

EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)

Terminated·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1·NCT01186328·6 enrolled

Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT05660473·100 enrolled

Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 1/2·NCT05192889·35 enrolled

Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00905034·37 enrolled

DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT04752163·17 enrolled

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

Recruiting·UUniversity of Washington·Phase 2·NCT05453500·30 enrolled

Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)

Completed·CChildren's Oncology Group·Phase 1·NCT03792256·12 enrolled

German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93)

Completed·GGoethe University·Phase 4·NCT00199069·720 enrolled

Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00866749·120 enrolled

Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT02420717·11 enrolled

Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)

Recruiting·UUniversity of Chicago·Phase 2·NCT04747912·25 enrolled

Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT01424982·88 enrolled

German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)

Completed·GGoethe University·Phase 4·NCT00198991·1,883 enrolled

LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive

Completed·PPETHEMA Foundation·Phase 4·NCT00526305·100 enrolled

Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia

Terminated·EEhab L Atallah·Phase 1·NCT01887587·5 enrolled

Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab

Completed·JJohann Wolfgang Goethe University Hospital·Phase 4·NCT00199004·60 enrolled

Diffuse Large B-Cell Lymphoma16 trials

Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

Terminated· Pfizer logo

Pfizer·Phase 2·NCT02855359·24 enrolled

The Palliative Benefit of Involved-site Radiotherapy for Patients With Advanced-stage Diffuse Large B-cell Lymphoma

Unknown status·WWuhan University·Phase 3·NCT02449278·120 enrolled

ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma

Terminated·DDeepa Jagadeesh·Phase 1/2·NCT04517435·13 enrolled

Show 13 more trials

Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma

Completed·SSamsung Medical Center·Phase 2·NCT02670616·24 enrolled

Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma

Recruiting·LLi Zhiming·Phase 2·NCT05422066·50 enrolled

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT03003520·46 enrolled

A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Completed· Roche logo

Roche·Phase 2·NCT04660799·50 enrolled

Decitabine Plus R-CHOP in Diffuse Large B-cell Lymphoma

Unknown status·RRuijin Hospital·Phase 1/2·NCT02951728·58 enrolled

The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.

Not yet recruiting·TThe First Hospital of Jilin University·N/A·NCT05990985·20 enrolled

Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.

Completed·GGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea·Phase 2·NCT01848132·121 enrolled

A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

Active, not recruiting· Roche logo

Roche·Phase 3·NCT03274492·1,000 enrolled

A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

Completed· Roche logo

Roche·Phase 1/2·NCT02596971·91 enrolled

R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma

Terminated·LLymphoma Study Association·Phase 3·NCT00135499·138 enrolled

A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)

Terminated· Roche logo

Roche·Phase 3·NCT01287741·1,418 enrolled

Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma

Completed·GGruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie·Phase 2·NCT00556127·94 enrolled

Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Diffuse Large B-cell Lymphoma

Unknown status·WWuhan University·Phase 3·NCT02449265·160 enrolled

Follicular Lymphoma10 trials

Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular Lymphoma

Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06474481·30 enrolled

Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma

Completed·TTrans Tasman Radiation Oncology Group·Phase 3·NCT00115700·150 enrolled

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT06911502·400 enrolled

Show 7 more trials

A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT02343536·59 enrolled

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma

Active, not recruiting· Gilead logo

Gilead·Phase 3·NCT05371093·231 enrolled

A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients

Completed·UUniversity of Liverpool·Phase 3·NCT01303887·680 enrolled

Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma

Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06704555·20 enrolled

An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma

Completed· Roche logo

Roche·Phase 4·NCT03817853·114 enrolled

Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Follicular Lymphoma

Unknown status·WWuhan University·Phase 3·NCT02449252·120 enrolled

A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)

Completed· Roche logo

Roche·Phase 3·NCT01889069·159 enrolled

Mantle Cell Lymphoma8 trials

Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study

Completed· Teva logo

Teva·Phase 3·NCT00877006·447 enrolled

R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma

Completed·UUniversity of Miami·Phase 2·NCT00450801·22 enrolled

Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00433537·77 enrolled

Show 5 more trials

Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma

Completed·UUniversity of Miami·Phase 2·NCT00878254·25 enrolled

Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years

Completed·FFrench Innovative Leukemia Organisation·Phase 2·NCT00285389·39 enrolled

EDOCH Alternating With DHAP for New Diagnosed Younger MCL

Completed·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 4·NCT02858804·55 enrolled

Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00477412·107 enrolled

Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00101101·43 enrolled

48 more indications

Treatment5 trials

Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL

Not yet recruiting·PPETHEMA Foundation··NCT06175702·150 enrolled

A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors

Terminated·—·Phase 2·NCT02110069·4 enrolled

Genotype-guided Treatment in DLBCL

Recruiting·RRuijin Hospital·Phase 3·NCT05351346·1,100 enrolled

Show 2 more trials

Treatment of Tumors of the Choroid Plexus Epithelium

Terminated·MM.D. Anderson Cancer Center·Phase 3·NCT00500890·2 enrolled

LAL-BR/2001: Study Treatment to Low Risk ALL

Completed·PPETHEMA Foundation·Phase 4·NCT00526175·150 enrolled

Neuroblastoma4 trials

Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas

Completed·—·Phase 2·NCT00165139·20 enrolled

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03786783·42 enrolled

High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 3·NCT04221035·800 enrolled

Show 1 more trial

Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma

Terminated·SSouth Plains Oncology Consortium·Phase 1·NCT02163356·4 enrolled

Chemotherapy4 trials

A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults

Unknown status·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT02611492·265 enrolled

Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP)

Terminated·UUniversity of Miami·Phase 2·NCT00450385·57 enrolled

A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL

Terminated·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1/2·NCT01483690·23 enrolled

Show 1 more trial

Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI)

Completed·MM.D. Anderson Cancer Center·N/A·NCT00410488·51 enrolled

Efficacy3 trials

To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan

Completed·CCelltrion·Phase 3·NCT02162771·140 enrolled

Evaluate PKs and Efficacy Assessment of Palifermin in Patients With Sarcoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00267046·49 enrolled

Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSL

Active, not recruiting· Ono Pharmaceutical Co. Ltd logo

Ono Pharmaceutical Co. Ltd·Phase 1·NCT06541665·20 enrolled

Newly Diagnosed3 trials

Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL

Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT04835870·78 enrolled

Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors

Unknown status·LLiaoning Cancer Hospital & Institute·Phase 2·NCT05887726·30 enrolled

Brentuximab for Newly Diagnosed Hodgkin Disease

Completed·MMitchell Cairo·Phase 2·NCT02398240·40 enrolled

Multiple Myeloma3 trials

Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma

Completed·OOhio State University Comprehensive Cancer Center·Phase 2·NCT00201695·12 enrolled

Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma

Terminated· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT00441168·30 enrolled

UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

Completed·UUniversity of Arkansas·Phase 3·NCT00083551·668 enrolled

Leukemia3 trials

CINJALL: Treatment for Children With Acute Lymphocytic Leukemia

Completed·RRutgers, The State University of New Jersey·Phase 2·NCT00176462·60 enrolled

Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00038610·54 enrolled

Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents

Active, not recruiting·UUniversity Hospital Muenster·Phase 3·NCT03206671·650 enrolled

Adult Acute Lymphoblastic Leukemia3 trials

Treatment of High Risk Adult Acute Lymphoblastic Leukemia

Completed·PPETHEMA Foundation·Phase 4·NCT00853008·100 enrolled

Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia

Completed·RRuijin Hospital·Phase 4·NCT01358253·100 enrolled

High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)

Unknown status·JJapan Adult Leukemia Study Group·Phase 3·NCT00131027·240 enrolled

Induction Chemotherapy2 trials

Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL

Unknown status·EEuropean Mantle Cell Lymphoma Network·Phase 3·NCT00209209·570 enrolled

Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL

Completed·—·Phase 1·NCT01523977·22 enrolled

Relapsed or Refractory2 trials

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

Completed· Novartis logo

Novartis·Phase 2·NCT02684058·151 enrolled

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

Recruiting·—·Phase 1/2·NCT06709495·63 enrolled

Hematologic Malignancies2 trials

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Recruiting·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1·NCT05476770·54 enrolled

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Recruiting·—·Phase 1·NCT05292664·30 enrolled

Medulloblastoma2 trials

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT01878617·660 enrolled

Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT02212574·6 enrolled

Advanced Stage2 trials

Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL

Completed·—·Phase 1/2·NCT00379574·49 enrolled

HD12 for Advanced Stages

Completed·UUniversity of Cologne·Phase 3·NCT00265031

Chidamide2 trials

Chidamide Plus R-CHOP in Elderly DLBCL

Unknown status·RRuijin Hospital·Phase 2·NCT02753647·49 enrolled

Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT03553238·70 enrolled

CHOP2 trials

AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH

Enrolling by invitation·TTianjin Medical University Cancer Institute and Hospital·Phase 3·NCT05678933·200 enrolled

Ph II CHOP+Velcade in Mediastinal LBCL

Terminated·—·Phase 2·NCT00361621·3 enrolled

DLBCL2 trials

R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL

Unknown status·NNanfang Hospital, Southern Medical University·Phase 3·NCT03018626·402 enrolled

Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A

Completed· Roche logo

Roche·Phase 3·NCT02406092·139 enrolled

Refractory Solid Tumors2 trials

Metformin in Children With Relapsed or Refractory Solid Tumors

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT01528046·26 enrolled

Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors

Suspended·NNational Cancer Institute (NCI)·Phase 1/2·NCT04890093·64 enrolled

Ewing sarcoma2 trials

Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01864109·83 enrolled

Irinotecan and Temozolomide for Ewing Sarcoma

Unknown status·PPeking University People's Hospital·Phase 2·NCT03359005·60 enrolled

Efficacy and Safety2 trials

Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT06387121·53 enrolled

A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL

Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06516978·528 enrolled

Stem Cell Transplant2 trials

Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00051311·62 enrolled

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00074490·442 enrolled

T-cell acute lymphoblastic leukemia2 trials

Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT06210750

A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT03384654·47 enrolled

Acute Leukemia of Ambiguous Lineage1 trial

Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT04440267·50 enrolled

Langerhans Cell Histiocytosis1 trial

Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis

Recruiting·WWest China Second University Hospital·N/A·NCT07431060·120 enrolled

Relapsed/Refractory1 trial

Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL

Completed·—·Phase 1·NCT03349281·6 enrolled

Lymphoproliferative Disorder1 trial

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

Recruiting·JJennifer Amengual·Phase 2·NCT06954805·30 enrolled

Primitive Neuroectodermal Tumor1 trial

Concurrent Carboplatin and Reduced Dose Craniospinal Radiation for Medulloblastoma and Primitive Neuroectodermal Tumor (PNET)

Completed·UUniversity of Colorado, Denver·Phase 2·NCT01542736·8 enrolled

Elderly Patients1 trial

R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL

Completed·FFondazione Italiana Linfomi - ETS·Phase 3·NCT01148446·226 enrolled

Acute Leukemia1 trial

Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02135874·16 enrolled

Safety and Efficacy1 trial

Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT03283202·35 enrolled

Richter Transformation1 trial

Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial

Not yet recruiting·SSWOG Cancer Research Network·Phase 3·NCT07220187·102 enrolled

Randomized1 trial

Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial

Recruiting·FFei Li·Phase 2·NCT06700798·90 enrolled

Hodgkins lymphoma1 trial

Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma

Completed·UUniversity of Cologne·Phase 2·NCT00284271·65 enrolled

EBV-Positive DLBCL, Nos1 trial

Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT04181489·55 enrolled

Wilms tumor1 trial

Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)

Recruiting·CCentre Oscar Lambret·Phase 1/2·NCT05384821·28 enrolled

B-cell Malignancies1 trial

Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies

Completed·—·Phase 1·NCT01760226·4 enrolled

Pediatric Solid Tumors1 trial

A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors

Completed·—·Phase 1·NCT00786669·13 enrolled

Tumour1 trial

Paediatric Hepatic International Tumour Trial

Active, not recruiting·UUniversity of Birmingham·Phase 3·NCT03017326·450 enrolled

Rhabdomyosarcoma1 trial

Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT01871766·115 enrolled

Infants1 trial

Vincristine Pharmacokinetics in Infants

Active, not recruiting·CChildren's Oncology Group··NCT05359237·83 enrolled

Retinoblastoma1 trial

Pilot Study of Topotecan/Vincristine With Subconjunctival Carboplatin for Patients With Bilateral Retinoblastoma

Withdrawn·—·N/A·NCT00980551

Toxicity1 trial

CHildren Treated With Vincristine: A Trial Regarding Pharmacokinetics, DNA And Toxicity of Targeted Therapy In Pediatric Oncology Patients.

Unknown status·—·Phase 4·NCT05844670·100 enrolled

Brentuximab Vedotin1 trial

A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms

Completed· Pfizer logo

Pfizer·Phase 1·NCT01309789·39 enrolled

Olverembatinib1 trial

A Study of Olverembatinib in the Treatment of Ph+ ALL

Unknown status·CChen Suning·Phase 2·NCT05466175·55 enrolled

Lymphoid Malignancies1 trial

Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach

Terminated·NNew Mexico Cancer Research Alliance·Phase 2·NCT00250718·17 enrolled

Combination Therapy1 trial

Combination Therapy of Anthracyclines for Children With Nephroblastoma

Not yet recruiting·SShengjing Hospital·Phase 4·NCT03892330·120 enrolled

Solid Tumors1 trial

UGT1A1 Genotype-drien Phase I Study of Irinotecan in VIT Regimen for the Treatment of Pediatric R/R Solid Tumors

Recruiting·SSun Yat-sen University·Phase 1·NCT06760117·39 enrolled

Real-world Study1 trial

A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL

Recruiting·RRuijin Hospital··NCT05899621·332 enrolled

Unspecified1 trial

131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat

Completed·NNew Approaches to Neuroblastoma Therapy Consortium·Phase 2·NCT02035137·114 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 1, 1982

ONCOVIN

NDA NDA014103

Aug 9, 2012

MARQIBO KIT

NDA NDA202497

Sources

References

[1]
ClinicalTrials.gov — 441 trial records for Vincristine. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Oncovin drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Vincristine compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Vincristine. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA202497). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Tubulin Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Eli Lilly

Oncovin

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q1 2027

Q2 2027

Trials by Indication[1]

Lymphoma52 trials

Acute Lymphoblastic Leukemia33 trials

Diffuse Large B-Cell Lymphoma16 trials

Follicular Lymphoma10 trials

Mantle Cell Lymphoma8 trials

Treatment5 trials

Neuroblastoma4 trials

Chemotherapy4 trials

Efficacy3 trials

Newly Diagnosed3 trials

Multiple Myeloma3 trials

Leukemia3 trials

Adult Acute Lymphoblastic Leukemia3 trials

Induction Chemotherapy2 trials

Relapsed or Refractory2 trials

Hematologic Malignancies2 trials

Medulloblastoma2 trials

Advanced Stage2 trials

Chidamide2 trials

CHOP2 trials

DLBCL2 trials

Refractory Solid Tumors2 trials

Ewing sarcoma2 trials

Efficacy and Safety2 trials

Stem Cell Transplant2 trials

T-cell acute lymphoblastic leukemia2 trials

Acute Leukemia of Ambiguous Lineage1 trial

Langerhans Cell Histiocytosis1 trial

Relapsed/Refractory1 trial

Lymphoproliferative Disorder1 trial

Primitive Neuroectodermal Tumor1 trial

Elderly Patients1 trial

Acute Leukemia1 trial

Safety and Efficacy1 trial

Richter Transformation1 trial

Randomized1 trial

Hodgkins lymphoma1 trial

EBV-Positive DLBCL, Nos1 trial

Wilms tumor1 trial

B-cell Malignancies1 trial

Pediatric Solid Tumors1 trial

Tumour1 trial

Rhabdomyosarcoma1 trial

Infants1 trial

Retinoblastoma1 trial

Toxicity1 trial

Brentuximab Vedotin1 trial

Olverembatinib1 trial

Lymphoid Malignancies1 trial

Combination Therapy1 trial

Solid Tumors1 trial

Real-world Study1 trial

Unspecified1 trial

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News